← Human Trials & Peer-Reviewed Studies
Cutaneous responses to substance P and calcitonin gene-related peptide in chronic urticaria: the effect of cetirizine and dimethindene
Plain-language guide to PMID 10195357 (1999): double-blind randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide) and Substance P.
Key Facts
- PMID
- 10195357
- Journal
- Allergy
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Borici-Mazi R et al. (3 authors)
- DOI
- 10.1034/j.1398-9995.1999.00726.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied CGRP (Calcitonin Gene-Related Peptide) and Substance P in this randomized controlled trial publication.
The purpose of this study was to investigate the cutaneous responses to substance P (SP) and calcitonin gene-related peptide (CGRP) in delayed pressure urticaria patients (DPUpt) and chronic idiopathic urticaria patients (CIUpt) compared to healthy adults (HA), and also to evaluate the effect of H1-antagonists on these responses.
Why It Was Studied
Neuropeptides appear to participate in the pathogenesis of chronic urticaria.
Who Took Part
The age groups tagged for this paper are adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.
As a double-blind CGRP (Calcitonin Gene-Related Peptide) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with CGRP (Calcitonin Gene-Related Peptide) could be set against what happens without it.
Each person switched between CGRP (Calcitonin Gene-Related Peptide) and the comparison at some point, usually with a gap in between.
Wheal (W) and flare (F) reactions to intradermally (ID) injected SP, CGRP, histamine (H), and diluent controls were evaluated in nine CIUpt, nine DPUpt, and nine HA at 3, 7, 15, 30, 60, and 120 min after injection.
What Was Measured
PubMed files the paper under topics including Calcitonin Gene-Related Peptide, Chronic Disease, Histamine H1 Antagonists, Hypersensitivity, Delayed, Skin Physiological Phenomena, Substance P and Urticaria.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) and Substance P.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1999 (Allergy), a journal based in Denmark.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page and the Substance P compound page, all human trials.
Our Notes on the Compounds
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Substance P: An 11-amino-acid neuropeptide involved in pain signaling and inflammation; given in research studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.